Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2020 08:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Closing of Collaboration and Share Purchase Agreements with Biogen

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
September 30, 2020 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics to Host Webinar on Transporting Biotherapeutics Across the Blood-Brain Barrier

— Webinar scheduled for Thursday, October 15th at 1:00 p.m. Eastern Time — SOUTH SAN FRANCISCO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical...
August 07, 2020 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
August 06, 2020 08:07 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients

DNL151 selected to advance into two late stage studies in Parkinson’s disease in patients with a kinase activating mutation in LRRK2 and in patients with sporadic diseaseDenali and collaboration...
July 29, 2020 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients

Dosing of DNL758 (SAR443122) has commenced in a randomized, double-blind, placebo-controlled Phase 1b trial to evaluate safety and effect on the immune system in severe COVID-19DNL758, discovered by...
June 09, 2020 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi

Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b)Denali and Sanofi intend to accelerate DNL788 for...
May 27, 2020 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine

Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with DNL310 (ETV:IDS), the...
May 07, 2020 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update

SOUTH SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the...
April 02, 2020 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
February 27, 2020 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...